Quantcast

Latest OSI Pharmaceuticals Stories

2008-09-08 09:00:52

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the appointment of Nicholas Bacopoulos, Ph.D., to its Board of Directors. Dr.

2008-09-04 12:00:07

Osi Pharmaceuticals has started a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the company is developing for the treatment of type 2 diabetes.

2008-09-03 09:00:08

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.

2008-07-16 12:00:20

OSI Pharmaceuticals has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the Torc1 and Torc2 complexes that inhibits the kinase activity associated with mTOR.

2008-07-15 09:00:16

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin).

2008-06-20 12:00:07

Osi Pharmaceuticals has initiated the first-in-human clinical study of its development compound PSN602, an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.

2008-06-20 00:00:06

OSI Pharmaceuticals, Inc. (Investors/Media) Kathy Galante, 631-962-2043 or (Media) Kim Wittig, 631-962-2135 or Burns McClellan (Representing OSI) Justin Jackson/Kathy Nugent (Media) 212-213-0006 Logo: http://www.osip.com OSI Pharmaceuticals, Inc.

2008-06-19 09:00:08

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated the first-in-human clinical study of its development compound PSN602.

2006-08-29 08:24:22

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S.

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S.


Word of the Day
bawbee
  • A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
  • (in plural) Money; cash.
Related